co nyse qq
lilli announc loxo acquisit gain target cancer
drug chang fair valu estim
updat forecast estim jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim jan
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
innov cultur strong financi commit
develop next gener drug set compani apart
peer fuel long-term growth follow steep
patent cliff lilli growth prospect improv
compani launch sever new blockbust patent loss
fade
lilli intern pipelin well posit mitig patent
loss next decad compani tend spend
sale financ develop effort new drug
much higher midteen industri averag robust
pipelin result lilli strong commit research
believ recent approv diabet drug trulic tradjenta
jardianc immunolog drug taltz olumi hold
highest sale potenti lilli new drug also sever lilli
late-stag cancer drug cyramza verzenio
develop blockbust addit clinic data hold
lilli strong entrench insulin product also help
compani deal patent loss unlik tradit drug
lilli insulin drug hard copi gener creat
barrier entri noninsulin produc larg
up-front invest need creat scale effici
lilli longer-act biosimilar insulin help compani
secur market share
compani take hard look bottom line
combin cost save expect top-lin growth lilli
aim reach oper margin believ
achiev pipelin success lilli expect increas
gross margin product initi greater
capac util may prove challeng
patent expir high-margin ciali alimta certain market
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
eli lilli pharmaceut compani focu neurosci
endocrinolog oncolog immunolog lilli key product includ
alimta cancer forteo osteoporosi jardianc trulic humalog
humulin diabet ciali erectil dysfunct also lilli
hold strong posit anim pharmaceut market plan
divest late
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qq
lilli announc loxo acquisit gain
cancer drug chang fair valu estim jan
announc acquisit loxo oncolog
billion expect major chang fair
valu estim base deal expect revenu
acquir cancer drug offset purchas price
increas expenditur strateg deal
bring lilli target cancer drug focus tumor
mutat trk ret btk fit well
lilli strong posit oncolog alreadi approv
cancer drug deal help fill lilli late-stag
competit advantag wide moat strengthen
portfolio drug carri strong price power loxo
approv drug vitrakvi price close
per annual cours treatment
target smaller patient group strong efficaci
drug support continu price power robust
sale vitrakvi follow-on drug partner
bayer close split profit drug
target trk posit cancer solid tumor
expect peak annual sale close billion loxo
late-stag drug target cancer ret fusion
lung cancer higher rate thyroid cancer
drug alreadi shown strong data non-smal cell
lung cancer respons rate refractori
patient popul alreadi taken three
therapi averag project drug reach peak
sale million annual potenti
registr phase ii data like late drug could
reach market addit loxo last later
stage drug target cancer btk mutat
ascrib sale potenti drug
early-stag data expect later
rais fair valu estim
per share base compel phase data dual
receptor agonist look pois
offer strong therapeut option patient
oral drug model peak
probability-weight sale approach
billion overal compani look well-posit drive
top-lin growth project annual sale increas
next decad result new drug launch
offset patent loss particular outlook
immunolog drug taltz olumi look strong
clinic data support drug becom leader
immunolog outsid immunolog expect diabet
drug jardianc trulic along cancer drug
cyramza becom increasingli import driver cash
flow particular jardianc look pois hit peak sale
project billion report boehring
ingelheim base strong cardiovascular data anoth
import point drive valuat cost control
increasingli think lilli abl meet estim
achiev oper margin
improv
outcom oper cost control depend new
revenu associ success recent launch
drug pipelin expect lilli reach goal
addit estim weight cost capit lilli
line compani peer group
larg base low volatil cash flow
divers inelast product portfolio rate lilli
uncertainti medium bit higher
pharma peer group partli high product
concentr risk surround compani pipelin
repres one fourth sale end
fair valu estim bull case
probabl bear case probabl project
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qq
cost-cut patent loss reduc margin
pressur lost high-margin drug sale overal lilli
establish product line creat enorm cash flow
need fund averag million develop
cost per new drug addit compani power
distribut network set compani strong partner
smaller drug compani lack lilli resourc lilli
entrench insulin franchis creat ad layer
competit advantag
competit seem mani year away due complex
gain gener approv insulin high cost
build need economi scale insulin product
given deceler patent loss strong pipelin
believ moat trend stabl next three
year compani key patent loss includ erectil
dysfunct drug ciali cardiovascular drug effient
potenti cancer drug alimta patent loss
next three year affect close total sale
compani strong pipelin combin stabl current
market drug lead annual revenu
growth period pipelin side
expect billion peak annual sale psoriasi
drug taltz rheumatoid arthriti drug olumi also
strong cardiovascular data lilli diabet drug
jardianc approv drive drug peak
annual sale billion
macro environ lilli sever headwind
make solid strateg move address challeng
neg side risk-sensit food drug
administr gener approv safe drug
drug high-ne area cancer also
managed-car organ pharmaci benefit
manag consolid past decad
use grow size demand lower drug price
reduc coverag less innov drug forc drug
firm push true innov reduc power
fair valu estim rel base case
scenario analysi show moder varianc henc
medium uncertainti rate factor affect
scenario analysi includ degre success
brand drug pipelin magnitud market
pressur current market drug larg amount
valuat driven pipelin success new drug
launch clinic trial amplifi impact lilli
patent economi scale power distribut
drug carri strong price power enabl firm
gener return invest capit excess cost
capit patent give compani time
develop next gener drug gener
mean compani top drug repres moder
amount total sale largest drug humalog
repres total sale set manag
cash flow declin new product mitig gener
competit also lilli oper structur allow
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qq
lilli distribut network govern
evalu compar effect program
aggress price negoti rais bar futur
innov lilli sever headwind pipelin
hold sever biolog drug hold much stronger
competit advantag tradit small molecul
compani pipelin focus
innov treatment area unmet medic need
payer coverag price power remain strong
outsid pipelin compani strong insulin franchis
sale carri extra protect award
biolog economi scale need produc
rel lower-pr drug also compani
well-entrench anim health busi sale
oper matur stabl busi
experienc signific chang
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qq
olilli launch new immunolog drug taltz
olumi offer better efficaci stronger
safeti profil tnf drug like set
olilli divestitur anim healthcar group
enabl firm focu higher-margin human
olilli increas focu develop drug
unmet medic indic neurolog oncolog
strategi improv success rate
food drug administr drive strong price
olilli lag immuno-oncolog market may
creat competit headwind older cancer
osever lilli recent launch diabet drug
year behind competit launch
lack differenti could slow market share
oth alimta composit matter patent expir
could bring gener market
weaker patent expir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qq
equival begin period
total avail debt servic
oblig commit
total oblig commit
strong cash flow deriv stabl diversifi
product portfolio remain solid financi foot
expect compani debt/ebitda level fall
project level time
time also expect debt/capit ratio
fall close cash flow
accru year strong growth prospect
expect lilli need make major acquisit
drive growth nevertheless expect
acquisit augment growth compani
adjust free
gener
gener revolv adjust
commit
gener
manufactur brand-nam drugmak also
govern managed-car organ continu
consolid purchas power exert price
challeng liabil lawsuit patent risk
cancer drug alimta sale elev
patent strong composit matter patent
increas likelihood earlier-than-expect gener
competit also strong data novo new drug
like weigh growth prospect trulic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qq
view lilli stewardship rel standard
believ lilli use billion acquir imclon
like gener good return partnership
boehring ingelheim greatli improv strateg
outlook compani verdict still regard
lilli decis spend industry-lead amount
capit percentag sale research
develop pipelin look strong phase
data need determin return invest
lilli purchas price novarti anim healthcar
busi billion appear high increas
entrench anim health increas lilli
competit advantag well-posit industri
januari dave rick took helm
ceo follow smooth transit previou ceo
john lechleit retir rick bring strong experi
previous serv presid lilli biomedicin
group cover alzheim diseas urolog
immunolog musculoskelet diseas pain well
compani global market function rick
experi lilli date back join
compani busi develop associ dont
expect major chang transit senior
ceo/chairman board/
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qq
lilli investor day reinforc steadi outlook
current pipelin drug expect dec
investor day provid guidanc updat
pipelin larg match expect
expect major chang fair valu estim
moat rate continu view lilli fairli valu
compani strong stride research
develop continu support wide moat rate
heavili base abil creat next
gener innov drug carri strong price
overal view lilli strong posit diabet pain
immunolog support sever upcom data
point lead earn per share compound
annual growth rate next three year
diabet expect trulic label gain posit
cardiovascular data help defend
franchis novo competit drug longer term
provid
differenti efficaci diabet drug potenti
launch late
drug
launch cgrp migrain drug emgal competit
class group whole see rapid uptak
expect acut migrain drug lasmiditan gain approv
base strong late-stag data also expect
posit phase efficaci data ngf pain drug tanezumab
accept side effect profil
turn immunolog expect continu growth
taltz olumi driven new indic studi
head-to-head studi taltz versu tremfya
report expect endpoint
enabl taltz show superior due fast onset
action taltz remind similar drug taltz novarti
cosentyx anoth fail efficaci versu tremfya
time endpoint week also
expect posit data olumi atop dermat
set anoth growth avenu drug
led divers set new drug lilli post strong
pois steadi long-term growth
report third-quart result slightli ahead
consensu expect expect
signific chang fair valu estim
continu view stock fairli valu lilli post
strong earn growth quarter driven
top-lin growth lower expens percentag
sale believ growth larg factor
stock strong growth new product offset
declin older drug help support view
innov remain strong lilli continu reinforc
wide moat rate firm
divers group product led lilli strong growth
patent loss like slow growth key growth
driver lilli diabet drug trulic
repres compani largest drug total sale
expect drug continu grow due
under-penetrated diabet market competit novo
like caus trulic growth rate moder
also immunolog drug taltz olumi diabet drug
jardianc cancer drug verzenio show robust
growth signal one divers set growth
driver pharma growth driver
off-set gener pressur erectil dysfunct drug
ciali intensifi later year
solid expens manag strong pipelin set lilli
steadi long-term growth lilli oper
guidanc look increasingli achiev
caus amplifi growth rate bottom line
oper margin close also
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qq
lilli pipelin hold new potenti blockbust
 /posit
recommend europ lasmiditan like approv
pain tanezumab phase data well
new indic sever drug especi trulic
posit cardiovascular outcom base rewind
slightli rais lilli fve compel mid-stag
lilli present compel phase data dual gip/
receptor agonist annual meet
european associ studi diabet
rais lilli fair valu estim
incorpor posit data well recent
approv migrain drug emgal continu
think novo oral semaglutid look well posit
strong launch believ lilli
also see strong traction inject side begin
said think demand incretin-bas
therapi continu rise time horizon
make signific chang novo nordisk
model share novo look rel fairli valu
follow declin surround releas data
sever question evolut
incretin market could affect market share
nordisk price oral semaglutid signific discount
current inject option whether payer opt prefer
gener version victoza trulic formulari
around time potenti launch
specif lilli titrat dose
need suffici control nausea
maintain efficaci still uncertainti surround
gip mechan given previou failur firm
said potenti could expand obes set
even nash long run also novo
maintain wide moat note firm exposur
increas victoza ozemp soon oral
semaglutid grow strongli rel pressur insulin
biopharmaceut busi franchis
novo total sale grow
total sale
market grow strongli sinc
launch once-weekli therapi lilli trulic novo
nordisk ozemp also benefit strong
cardiovascular outcom data novo nordisk older
inject once-daili victoza market heavili
weight toward sale market growth
remain solidli launch ozemp
year victoza sale flatten slightli lilli trulic
still launch strongli above-market growth
lilli data surpass trulic efficaci also
show potenti surpass efficaci novo
ozemp best-in-class option test
sever dose show reduct
mg dose well weight loss
kg dose trulic look weak
comparison reduct kg weight
loss arm studi refer novo sustain
trial ozemp
show lower around weight loss
kg sustain trial specif show
superior measur lilli trulic
expect novo oral semaglutid perform strongli even
lilli launch oral market could
give firm greater access primari care physician
well opportun offer slightli discount price
drug three-year lead race
market novo oral semaglutid shown slightli
lower efficaci ozemp kilogram weight loss
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qq
reduct prove superior
victoza trulic highest mg dose test
pioneer pioneer measur
pharma moat outlook compani still strong
analysi pharma compani continu
see industri well posit strong econom
moat analysi reaffirm moat
rate increas bayer moat wide
narrow bayer divestitur materi scienc group
combin strong drug busi well-posit
bolster monsanto
acquisit led us upgrad moat rate wide
moat pharma compani
increas focu innov area unmet medic
need enabl strong price power off-set increas
negoti power pharmaci benefit manag
 restrict price develop market outsid
 drug carri patent protect allow firm
charg near monopolist price drug true price
power determin sever factor includ benefit
patient uniqu govern outsid
 pbm within increasingli push
back drug price medicin lack signific
benefit overal stronger drug uniqu
efficaci stronger drug price power result
major drug compani focus
develop effort area signific unmet medic
addit segment within pharma firm anim
health consum healthcar carri strong moat
augment moat strength deriv human brand
drug segment overal moat analysi guid
under-valued call bayer glaxosmithklin
valuat
complet overview pharma moat analysi
pleas see report pharma moat outlook compani
still strong posit analyz key point
around moat larg pharmaceut industri
lilli post strong result decid divest
post strong second-quart result ahead
consensu expect plan slightli
rais fair valu estim gener competit
pressur area lilli portfolio recent
launch drug off-set headwind lead
oper revenu growth due cost-
cut lilli bottom line grew year year
expect growth rate slow next
quarter gener competit intensifi especi
erectil dysfunct drug ciali expect lilli one
fastest-grow larg drug compani industri
annual revenu growth rate next
three year remain bullish immunolog drug taltz
shown clinic superior lead tnf
drug class also lilli diabet franchis remain
well posit expect growth drug trulic
quarter slow novo nordisk clinic
stronger drug ozemp gain traction howev expect
posit outcom studi rewind trulic
second half help mitig competit pressur
overal strong posit lilli innov new drug
platform combin strong entrench
matur drug help reinforc wide moat rate
firm
tandem earn releas lilli announc
decis spin anim healthcar busi elanco
second half major synergi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qq
human anim health busi less need
lean group stabil lilli beyond heavi
patent loss year expect lilli divest
divis within anim healthcar industri
believ elanco well posit competit
advantag standpoint valuat perspect
estim segment worth close
billion sever factor could affect valuat
overview competit dynam anim
healthcar market pleas see healthcar observ
titl deciph econom moat valuat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qq
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qq
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
